Page 2 - Nautilus Platform News Today

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) will post its quarterly earnings results before the market opens on Tuesday, May 2nd. Analysts expect Nautilus Biotechnology to post earnings of ($0.16) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Nautilus Biotechnology (NASDAQ:NAUT – Get […]

Sentinel Trust Co. LBA decreased its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) by 14.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 185,000 shares of the company’s stock after selling 30,000 shares during the […]

Standard BioTools (NASDAQ:LAB – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Earnings & Valuation This table compares Standard BioTools and […]

Susquehanna International Group LLP cut its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) by 35.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,818 shares of the company’s stock after selling 13,352 shares during the […]

Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 469,300 shares, a decline of 49.7% from the March 15th total of 932,300 shares. Based on an average trading volume of 125,900 shares, the days-to-cover ratio is […]

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Nautilus Biotechnology to similar businesses based on the strength of its earnings, institutional ownership, valuation, analyst recommendations, dividends, profitability and risk. Institutional & Insider Ownership […]

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to related companies based on the strength of its profitability, earnings, analyst recommendations, valuation, dividends, risk and institutional ownership. Earnings and Valuation This table compares […]

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) and Codex DNA (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations. Profitability This table compares Nautilus Biotechnology and Codex DNA’s […]

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare Nautilus Biotechnology to related companies based on the strength of its valuation, profitability, analyst recommendations, dividends, risk, institutional ownership and earnings. Institutional & Insider Ownership 47.9% of […]

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) and Olink Holding AB (publ) (NASDAQ:OLK – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Insider & Institutional Ownership 47.9% of Nautilus […]